EP1576145A4 - Bioinformatically detectable group of novel viral regulatory genes and uses thereof - Google Patents

Bioinformatically detectable group of novel viral regulatory genes and uses thereof

Info

Publication number
EP1576145A4
EP1576145A4 EP03811859A EP03811859A EP1576145A4 EP 1576145 A4 EP1576145 A4 EP 1576145A4 EP 03811859 A EP03811859 A EP 03811859A EP 03811859 A EP03811859 A EP 03811859A EP 1576145 A4 EP1576145 A4 EP 1576145A4
Authority
EP
European Patent Office
Prior art keywords
genes
vgam
vgr
novel
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03811859A
Other languages
German (de)
French (fr)
Other versions
EP1576145A2 (en
Inventor
Itzhak Bentwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/604,942 external-priority patent/US7696334B1/en
Priority claimed from US10/604,945 external-priority patent/US7696342B1/en
Priority claimed from US10/605,840 external-priority patent/US20070077553A1/en
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Publication of EP1576145A2 publication Critical patent/EP1576145A2/en
Publication of EP1576145A4 publication Critical patent/EP1576145A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a first group of novel genes, here identified as genomic address messenger or VGAM genes, and a second group of novel operon-like genes, here identified as viral genomic record or VGR genes. VGAM genes selectively inhibit translation of known `target' genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 1560 VGAM genes, and 205 VGR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting VGAM and VGR genes and specific functions and utilities thereof, for detecting expression of VGAM and VGR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
EP03811859A 2002-12-05 2003-11-26 Bioinformatically detectable group of novel viral regulatory genes and uses thereof Withdrawn EP1576145A4 (en)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US604943 2000-06-27
US308778 2002-11-26
US31018802A 2002-12-05 2002-12-05
US310188 2002-12-05
US44124103P 2003-01-17 2003-01-17
US41123003P 2003-01-17 2003-01-17
US441241P 2003-01-17
US411230P 2003-01-17
US45778803P 2003-03-27 2003-03-27
US457788P 2003-03-27
US604945 2003-08-27
US604942 2003-08-27
US10/604,942 US7696334B1 (en) 2002-12-05 2003-08-27 Bioinformatically detectable human herpesvirus 5 regulatory gene
US10/604,945 US7696342B1 (en) 2002-11-26 2003-08-27 Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US10/604,944 US7217807B2 (en) 2002-11-26 2003-08-28 Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US604944 2003-08-28
US10/604,943 US7790867B2 (en) 2002-12-05 2003-08-28 Vaccinia virus-related nucleic acids and microRNA
US10/604,984 US7759478B1 (en) 2002-12-05 2003-08-29 Bioinformatically detectable viral regulatory genes
US604984 2003-08-29
US605838 2003-10-30
US10/605,840 US20070077553A1 (en) 2003-10-30 2003-10-30 Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US605840 2003-10-30
US10/605,838 US20080188428A1 (en) 2002-11-26 2003-10-30 Bioinformatically detectable group of novel hiv regulatory genes and uses thereof
PCT/IL2003/000998 WO2004048511A2 (en) 2002-11-26 2003-11-26 Bioinformatically detectable group of novel viral regulatory genes and uses thereof

Publications (2)

Publication Number Publication Date
EP1576145A2 EP1576145A2 (en) 2005-09-21
EP1576145A4 true EP1576145A4 (en) 2007-06-13

Family

ID=39684558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03811859A Withdrawn EP1576145A4 (en) 2002-12-05 2003-11-26 Bioinformatically detectable group of novel viral regulatory genes and uses thereof

Country Status (4)

Country Link
US (6) US7790867B2 (en)
EP (1) EP1576145A4 (en)
AU (1) AU2003302409A1 (en)
WO (1) WO2004048511A2 (en)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
JP2006507841A (en) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
WO2004047764A2 (en) * 2002-11-22 2004-06-10 University Of Massachusetts Modulation of hiv replication by rna interference
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8288523B2 (en) 2003-09-11 2012-10-16 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
GB2442373B (en) * 2003-11-26 2008-10-22 Univ Massachusetts Sequence -specific inhibition of small rna function
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US7416842B2 (en) 2004-04-05 2008-08-26 The Rockefeller University DNA virus microRNA
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
DK1735459T3 (en) * 2004-04-07 2012-05-29 Exiqon As Methods for Quantification of MicroRNAs and Small Interfering RNAs
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
AU2005245516A1 (en) * 2004-05-20 2005-12-01 Warnex Research Inc. Polynucleotides for the detection of escherichia coli 0157:h7 and escherichia coli 0157:nm verotoxin producers
ES2392445T3 (en) 2004-07-13 2012-12-10 Gen-Probe Incorporated Compositions and methods for the detection of hepatitis A virus nucleic acid
EP2631293A3 (en) 2005-04-29 2013-11-20 The Rockefeller University Human microRNAs and methods for inhibiting same
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CA2630738C (en) * 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US8014956B2 (en) 2005-12-30 2011-09-06 Industrial Technology Research Institute MicroRNA precursors
WO2007089584A2 (en) * 2006-01-26 2007-08-09 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
EP1989328A4 (en) * 2006-02-23 2009-07-01 Univ Johns Hopkins Bbs10 related diagnostic methods and reagents for bardet-biedl syndrome
EP2006382B1 (en) * 2006-04-11 2016-08-03 Eisai R&D Management Co., Ltd. Dopamine-producing neuron progenitor cell marker 187a5
JP5693004B2 (en) * 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル Method for suppressing malignancy of tumor cells using microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
EP1897891A1 (en) * 2006-09-11 2008-03-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
US8541169B2 (en) 2006-10-10 2013-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
US20100129804A1 (en) * 2006-11-08 2010-05-27 Chinnaiyan Arul M Spink1 as a prostate cancer marker and uses thereof
US20080171719A1 (en) * 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
NZ577759A (en) * 2007-01-11 2012-07-27 Genentech Inc Genetic variations of tyrosine kinase 2 resulting in an activated catalytic domain are associated with colon and stomach cancer
WO2008089265A2 (en) * 2007-01-17 2008-07-24 University Of Georgia Research Foundation, Inc. Anti-viral methods and compositions
ES2432406T3 (en) * 2007-04-05 2013-12-03 Bayer Cropscience Nv Insect-resistant cotton plants and methods to identify them
CA2690643A1 (en) 2007-06-14 2008-12-18 Mirx Therapeutics Aps Oligonucleotides for modulation of target rna activity
ES2376509T3 (en) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan REPORTS OF GENES MIPOL 1-ETV1.
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2231165B1 (en) * 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
WO2009071680A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of mcl-1
DE102008013622A1 (en) * 2008-03-10 2009-09-17 Freie Universität Berlin Pharmaceutical composition for the diagnosis or treatment of the plasmocytoma
JP5689413B2 (en) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 5 'triphosphate oligonucleotide having blunt ends and uses thereof
US8488863B2 (en) * 2008-11-06 2013-07-16 Los Alamos National Security, Llc Combinational pixel-by-pixel and object-level classifying, segmenting, and agglomerating in performing quantitative image analysis that distinguishes between healthy non-cancerous and cancerous cell nuclei and delineates nuclear, cytoplasm, and stromal material objects from stained biological tissue materials
JP2012509675A (en) * 2008-11-25 2012-04-26 ジェン−プロウブ インコーポレイテッド Compositions and methods for detecting small RNAs and uses thereof
JP2012514475A (en) * 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Reproducible gene fusions in cancer
WO2010100437A2 (en) * 2009-03-05 2010-09-10 University Of Sheffield Production of protein
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
EP2966181B1 (en) * 2009-06-26 2018-02-14 Epigenomics AG Methods and nucleic acids for analysis of bladder carcinoma
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
US9938582B2 (en) * 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2985352A1 (en) * 2009-09-23 2016-02-17 Analytik Jena AG Method for in vitro recording and differentiation of pathophysiological states
US20110076685A1 (en) * 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
DE102009044085A1 (en) * 2009-09-23 2011-11-17 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
JP6175236B2 (en) * 2009-09-25 2017-08-09 カッパーアールエヌエー，インコーポレイテッド Treatment of FLG-related diseases by modulating the expression and activity of filaggrin (FLG)
EP2515947B1 (en) * 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
EP3578183B1 (en) 2010-03-24 2021-09-08 Phio Pharmaceuticals Corp. Rna interference in ocular indications
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
WO2011130371A1 (en) 2010-04-13 2011-10-20 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
EP2569054A4 (en) * 2010-05-11 2013-10-02 Hampton University Office Of General Counsel Apparatus, method and system for measuring prompt gamma and other beam-induced radiation during hadron therapy treatments for dose and range verificaton purposes using ionization radiation detection
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
DE102011009470A1 (en) * 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologically active nucleotide molecules for the targeted killing of cells, use thereof and application kit
WO2012106175A1 (en) * 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
US20160144003A1 (en) * 2011-05-19 2016-05-26 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
WO2012164401A1 (en) * 2011-06-03 2012-12-06 Genomic Vision Assessment of cancer risk based on rnu2 cnv and interplay between rnu2 cnv and brca1
CN103620036B (en) * 2011-06-09 2016-12-21 库尔纳公司 FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
JP6090937B2 (en) 2011-07-27 2017-03-08 国立大学法人京都大学 Novel dopaminergic neural progenitor cell marker
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
US9127040B2 (en) 2011-09-20 2015-09-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
FR2983212A1 (en) 2011-11-28 2013-05-31 Lfb Biotechnologies ANTI-FH APTAMERS, PROCESS FOR OBTAINING THEM AND USES THEREOF
US20140323581A1 (en) * 2011-12-05 2014-10-30 The Trustees Of Columbia University In The City Of New York Transcriptome wiring analysis in parkinson's disease and uses thereof
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
CN104066842A (en) * 2012-01-25 2014-09-24 独立行政法人科学技术振兴机构 Oligonucleotide for HIV detection, HIV detection kit, and HIV detection method
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
RU2730677C2 (en) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Compound for modulation of c9orf72 gene expression and use thereof
US9213947B1 (en) 2012-11-08 2015-12-15 23Andme, Inc. Scalable pipeline for local ancestry inference
US9836576B1 (en) 2012-11-08 2017-12-05 23Andme, Inc. Phasing of unphased genotype data
GB201304810D0 (en) * 2013-03-15 2013-05-01 Isis Innovation Assay
JP2016518126A (en) * 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Lone Star Virus
US9305257B2 (en) * 2013-05-20 2016-04-05 International Business Machines Corporation Adaptive cataclysms in genetic algorithms
US20160120941A1 (en) * 2013-05-31 2016-05-05 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
EP3004398B1 (en) * 2013-05-31 2019-11-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Real-time pcr point mutation assays for detecting hiv-1 resistance to antiviral drugs
SG11201602597YA (en) 2013-10-11 2016-05-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US9903940B2 (en) * 2013-12-30 2018-02-27 Qualcomm Incorporated Entrusted device localization scheme using ultrasound signatures
US9901478B2 (en) 2014-03-11 2018-02-27 Chine, Llc Methods and apparatuses for the external distraction in the assistance of spinal deformities
US10394828B1 (en) * 2014-04-25 2019-08-27 Emory University Methods, systems and computer readable storage media for generating quantifiable genomic information and results
GB201410693D0 (en) * 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
SG11201701655YA (en) * 2014-09-19 2017-04-27 Agency Science Tech & Res Differentiation of hepatocyte-like cells from stem cells
JP6867945B2 (en) 2014-10-03 2021-05-12 コールド スプリング ハーバー ラボラトリー Targeted enhancement of nuclear gene output
US9654308B2 (en) * 2014-11-19 2017-05-16 Intel Corporation Systems and methods for carrier frequency offset estimation for long training fields
US10616219B2 (en) * 2014-12-11 2020-04-07 FlowJo, LLC Single cell data management and analysis systems and methods
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016154028A1 (en) 2015-03-26 2016-09-29 Iversen Jacqueline M Methods and compositions to inhibit symptoms associated with veisalgia
CN107429250B (en) 2015-04-03 2022-03-01 Ionis制药公司 Compounds and methods for modulating expression of TMPRSS6
HUE057431T2 (en) 2015-04-03 2022-05-28 Univ Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
SG11201708468YA (en) 2015-04-16 2017-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US10185803B2 (en) * 2015-06-15 2019-01-22 Deep Genomics Incorporated Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network
EP3350328A1 (en) * 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017066657A1 (en) * 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
AU2017210726B2 (en) 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
US11753682B2 (en) 2016-03-07 2023-09-12 Father Flanagan's Boys'Home Noninvasive molecular controls
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
GB201609597D0 (en) 2016-06-01 2016-07-13 Univ Sheffield Therapy
CN109451729B (en) 2016-06-08 2022-03-22 哈佛学院院长及董事 Engineered viral vectors reduce induction of inflammation and immune responses
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
WO2018217933A1 (en) 2017-05-25 2018-11-29 FlowJo, LLC Visualization, comparative analysis, and automated difference detection for large multi-parameter data sets
US10906949B2 (en) * 2017-06-28 2021-02-02 The Cleveland Clinic Foundation Methods of treating spinal cord injury using a chondroitin sulfate proteoglycan (CSPG) reduction peptide (CRP) comprising a cell membrane penetrating domain, a CSPG binding domain, and a lysosome targeting domain
US10416226B2 (en) * 2017-08-03 2019-09-17 Globalfoundries Inc. Test response compaction scheme
PL3673080T3 (en) 2017-08-25 2024-03-11 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
MY202410A (en) 2017-09-01 2024-04-27 Venn Biosciences Corp Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
US20190102841A1 (en) 2017-10-04 2019-04-04 Servicenow, Inc. Mapping engine configurations with task managed workflows and grid user interfaces
WO2019094548A1 (en) 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
US11639503B2 (en) * 2017-11-30 2023-05-02 Ribomic Inc. Anti-chymase aptamer and use for same
MX2020009147A (en) 2018-03-02 2020-09-28 Ionis Pharmaceuticals Inc Modulators of irf4 expression.
CN112020556A (en) * 2018-03-21 2020-12-01 瑞泽恩制药公司 17 beta hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
SG11202101288TA (en) 2018-08-10 2021-03-30 Univ Massachusetts Modified oligonucleotides targeting snps
CN109097465B (en) * 2018-09-19 2021-06-08 蒲佐 Application of SNP (single nucleotide polymorphism) site of CLIP3 gene
CN109355408B (en) * 2018-09-26 2021-09-21 华南理工大学 Primer, kit and method for PSR (phosphosilicate receptor) detection of Escherichia coli type I Shiga toxin
BR112021005791A2 (en) 2018-09-26 2021-07-27 Greenlight Biosciences, Inc. beetle insect control
AU2019377855A1 (en) 2018-11-08 2021-06-03 Greenlight Biosciences, Inc. Control of insect infestation
CN111363783B (en) * 2018-12-26 2024-01-02 武汉康测科技有限公司 T cell receptor library high-throughput sequencing library construction and sequencing data analysis method based on specific recognition sequence
US11581060B2 (en) * 2019-01-04 2023-02-14 President And Fellows Of Harvard College Protein structures from amino-acid sequences using neural networks
CN109884007B (en) * 2019-02-18 2020-10-27 西安交通大学 Integrated synchronous DNA nano device and living cell multi-target imaging application and imaging method thereof
CN110327498B (en) * 2019-04-15 2021-02-02 北京大学口腔医学院 Active small molecule controlled release method based on liposome and application thereof
CN110592044B (en) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 Protein kinase Fused coding gene and application thereof in preventing and treating diamond back moth
CN110572216A (en) * 2019-09-17 2019-12-13 成都芯瑞科技股份有限公司 optical module APC control software implementation method
CN110596403B (en) * 2019-09-17 2022-12-16 中山大学附属第一医院 Specific protein marker for ovarian cancer diagnosis and preparation method thereof
EP4077666A1 (en) 2019-12-16 2022-10-26 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CN111024850B (en) * 2019-12-25 2022-06-14 贵州大学 Preparation and application of paraquat molecular imprinting solid-phase microextraction coating solution
WO2021216114A1 (en) 2020-04-22 2021-10-28 Houston Gene Therapeutics Llc Compositions for treatment of vascular disease
KR20230022409A (en) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. OPA1 antisense oligomers for the treatment of conditions and diseases
US11817176B2 (en) 2020-08-13 2023-11-14 23Andme, Inc. Ancestry composition determination
UY39417A (en) 2020-09-11 2022-03-31 Arrowhead Pharmaceuticals Inc ARNI AGENTS FOR INHIBITING DUX4 EXPRESSION, COMPOSITIONS OF SUCH AGENTS, AND METHODS OF USE
CN112400904B (en) * 2020-11-19 2021-06-25 山东农业大学 Application of miR-995 in lepidoptera pest control
CN112553054A (en) * 2020-12-10 2021-03-26 上海艾众生物科技有限公司 Cell separation apparatus for bioreactor
CN113106154B (en) * 2021-04-16 2022-10-25 上海市第一妇婴保健院 Application of PRMT3 in diagnosis or treatment of recurrent spontaneous abortion
GB202107586D0 (en) * 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
CA3174095A1 (en) 2021-06-23 2022-12-29 Vignesh Narayan HARIHARAN Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CN113234737A (en) * 2021-06-30 2021-08-10 安徽农业大学 Application of MYB transcription factor gene of tea tree in regulating and controlling caffeine biosynthesis of tea tree
CN114836580B (en) * 2022-06-02 2024-05-10 昆明理工大学 Multiplex qPCR detection primer combination for respiratory tract infectious disease pathogens
WO2024042042A1 (en) * 2022-08-24 2024-02-29 F. Hoffmann-La Roche Ag Compositions and methods for detecting monkeypox virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743364A2 (en) * 1995-05-18 1996-11-20 Commissariat A L'energie Atomique Nucleic acid fragments derived form the HIV-1 genome, corresponding fragments and their application as reactives for risk evaluation of HIV-1 mother-foetal transmission
EP1203826A2 (en) * 2000-10-30 2002-05-08 Tosoh Corporation Oligonucleotide for detection of HIV-1 and detection method

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6027880A (en) * 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
NO972006D0 (en) 1997-04-30 1997-04-30 Forskningsparken I Aas As New method for diagnosis of diseases
US6849431B2 (en) * 1997-07-25 2005-02-01 Ryoji Tamura Non-B, non-C, non-G hepatitis virus gene, polynucleotide, polypeptide, virus particle, method for isolating virus particle, and method for detecting virus
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU1681099A (en) * 1997-12-29 1999-07-19 Genena Ltd. A method for identifying and characterizing cells and tissues
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6107091A (en) * 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
EP1013775A1 (en) * 1998-12-21 2000-06-28 LUTZ, Hans Quantitative polymerase chain reaction using a fluorogenic real-time detection system
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
JP2003530309A (en) * 1999-10-26 2003-10-14 イミューソル インコーポレイテッド Ribozyme therapy for treating proliferative skin disease or proliferative eye disease
GB9925459D0 (en) 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
US6903247B2 (en) * 2000-02-08 2005-06-07 Cornell Research Foundation, Inc. Constitutive α-Tubulin promoter from coffee plants and uses thereof
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US6503756B1 (en) * 2000-09-22 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of syntaxin 4 interacting protein expression
US6692954B1 (en) * 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
HU230458B1 (en) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Rna interference mediating small rna molecules
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
WO2003070884A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc Conjugates and compositions for cellular delivery
SE519066C2 (en) 2001-05-21 2003-01-07 Sca Hygiene Prod Ab Absorbent articles provided with a belt comprising stiffening elements
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Rna interference mediated inhibition of map kinase genes
AU2003265978A1 (en) 2002-05-03 2003-11-17 Duke University A method of regulating gene expression
US20030228691A1 (en) 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
US20040106566A1 (en) 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
WO2004009779A2 (en) 2002-07-19 2004-01-29 University Of South Carolina Compositions and methods for the modulation of gene expression in plants
US20050059011A1 (en) 2002-08-07 2005-03-17 Sin Wun Chey Amplification and overexpression of oncogenes
CA2500472A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US7314750B2 (en) * 2002-11-20 2008-01-01 Affymetrix, Inc. Addressable oligonucleotide array of the rat genome
WO2005001128A2 (en) * 2003-04-11 2005-01-06 University Of Florida Research Foundation, Inc. Materials and methods for producing dna libraries and detecting and identifying microorganisms
EP1629124A2 (en) * 2003-06-05 2006-03-01 Wyeth Nucleic acid arrays for detecting multiple strains of a non-viral species
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US20060293267A1 (en) * 2005-04-13 2006-12-28 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743364A2 (en) * 1995-05-18 1996-11-20 Commissariat A L'energie Atomique Nucleic acid fragments derived form the HIV-1 genome, corresponding fragments and their application as reactives for risk evaluation of HIV-1 mother-foetal transmission
EP1203826A2 (en) * 2000-10-30 2002-05-08 Tosoh Corporation Oligonucleotide for detection of HIV-1 and detection method

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAPODICI J: "Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 169, October 2002 (2002-10-01), pages 5196 - 5201, XP002988100, ISSN: 0022-1767 *
DATABASE EMBL [online] 14 October 1996 (1996-10-14), "Sequence 3 from patent US 5512438.", retrieved from EBI accession no. EMBL:I19741 Database accession no. I19741 *
DATABASE GENESEQ [online] 23 April 1999 (1999-04-23), "HIV-1 TAR mimetic oligonucleotide 1346.", retrieved from EBI accession no. GSN:AAX05666 Database accession no. AAX05666 *
DATABASE GENESEQ [online] 25 March 1999 (1999-03-25), "HIV-1 RNA TAR sequence.", retrieved from EBI accession no. GSN:AAV81502 Database accession no. AAV81502 *
DATABASE GENESEQ [online] 9 September 1999 (1999-09-09), "HIV TAR derived RNA fragment.", retrieved from EBI accession no. GSN:AAX88048 Database accession no. AAX88048 *
GOTTWEIN E. ET AL: "viral and cellular MicroRNAs as dterminants of viral pathogenesis and immunity", CELL HOST & MICROBE, ELSEVIER, NL LNKD- DOI:10.1016/J.CHOM.2008.05.002, vol. 3, 12 June 2008 (2008-06-12), pages 375 - 387, XP002509429, ISSN: 1931-3128 *
NOVINA C D ET AL: "siRNA directed inhibition of HIV-1 infection", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 8, July 2002 (2002-07-01), pages 681 - 686, XP002955298, ISSN: 1078-8956 *
PARK W S ET AL: "Specific inhibition of HIV-1 gene expression by double-stranded RNA.", NUCLEIC ACIDS RESEARCH. SUPPLEMENT (2001) 2001, no. 1, 2001, pages 219 - 220 *
PARK WEE-SUNG ET AL: "Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference.", NUCLEIC ACIDS RESEARCH 15 NOV 2002, vol. 30, no. 22, 15 November 2002 (2002-11-15), pages 4830 - 4835, XP002430602, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
US7790867B2 (en) 2010-09-07
US7777022B2 (en) 2010-08-17
AU2003302409A1 (en) 2004-06-18
WO2004048511A3 (en) 2005-12-15
US20080188428A1 (en) 2008-08-07
US7217807B2 (en) 2007-05-15
US8207316B1 (en) 2012-06-26
US7759478B1 (en) 2010-07-20
US20040219515A1 (en) 2004-11-04
US20070031823A1 (en) 2007-02-08
WO2004048511A2 (en) 2004-06-10
US20070042381A1 (en) 2007-02-22
EP1576145A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
WO2004048511A3 (en) Bioinformatically detectable group of novel viral regulatory genes and uses thereof
WO2006126040A8 (en) Bacterial and bacterial associated mirnas and uses thereof
WO2009135093A3 (en) Rnase-h-based assays utilizing modified rna monomers
WO2001081622A3 (en) Diagnosis of diseases associated with dna repair
WO2002002807A8 (en) Diagnosis of diseases associated with cell signalling
WO2001071042A8 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
WO2001068911A8 (en) Diagnosis of diseases associated with the cell cycle
WO2009006478A3 (en) 6-disubstituted bicyclic nucleic acid analogs
WO2008009437A3 (en) Sdf-i binding nucleic acids
EP3040423A3 (en) Microrna and uses thereof
MX337801B (en) Mcp-i binding nucleic acids.
WO2009040113A3 (en) C5a BINDING NUCLEIC ACIDS
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
WO1996006949A3 (en) Nucleic acid hybridization assay probes targeted to mycoplasma pneumoniae nucleic acid
WO2007047482A3 (en) Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics
CA2506797A1 (en) Detectable labeled nucleoside analogs and methods of use thereof
WO2002012290A8 (en) Sid polypeptides binding to pathogenic strain of the hepatitis c virus
WO2002036828A3 (en) COMPOSITIONS AND SYSTEMS FOR IDENTIFYING AND COMPARING EXPRESSED GENES (mRNAs) IN EUKARYOTIC ORGANISMS
WO2008091283A3 (en) Viral inhibitory nucleotide sequences and vaccines
WO2002006487A3 (en) Regulatory sequences from meristematic cells
WO2001059108A3 (en) Inhibitors of apoptosis
WO2001016322A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2002064743A3 (en) Confirming the exon content of rna transcripts by pcr using primers complementary to each respective exon
WO2002044722A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001027298A3 (en) Sclerotinia-inducible genes and promoters and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/48 20060101AFI20051222BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070511

17Q First examination report despatched

Effective date: 20080118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110121